Key result
Early AVR shows no mortality benefit over surveillance, but reduces composite CV events.
Why the study?
The optimal timing of intervention in asymptomatic severe aortic stenosis remains controversial, as current guidelines support clinical surveillance while recent randomized trials suggest potential benefit from earlier aortic valve replacement.
Does early aortic valve replacement (SAVR or TAVR) reduce all-cause mortality and major cardiovascular events compared with conservative surveillance in patients with asymptomatic severe aortic stenosis?
Meta-Analysis (n=1,427)
Randomized controlled trials
Does early aortic valve replacement (SAVR or TAVR) reduce all-cause mortality and major cardiovascular events compared with conservative surveillance in patients with asymptomatic severe aortic stenosis?
In patients with asymptomatic severe aortic stenosis, early SAVR or TAVR significantly reduces composite cardiovascular events, cardiovascular mortality, heart failure hospitalization, and stroke compared with conservative surveillance, though the reduction in all-cause mortality did not reach statistical significance.
Answers are grounded in this paper and cite their sources.
Early AVR reduces hospitalizations and stroke versus surveillance in asymptomatic severe AS; challenges guideline-endorsed watchful waiting and supports updated RCTs.
Background: The optimal timing of intervention in asymptomatic severe aortic stenosis (AS) remains controversial. While current guidelines support clinical surveillance until symptom onset or ventricular dysfunction, recent randomized trials have suggested potential benefit from earlier aortic valve replacement (AVR). Objectives: To evaluate the efficacy of early AVR, including surgical AVR (SAVR) and transcatheter AVR (TAVR), compared with conservative surveillance in patients with asymptomatic severe AS. Methods: We performed a systematic review and meta-analysis of randomized controlled trials comparing early AVR versus conservative management in asymptomatic severe AS. Four trials were included: RECOVERY long-term follow-up, AVATAR long-term follow-up, EARLY TAVR, and EVOLVED. Random-effects restricted maximum likelihood models were used to pool hazard ratios (HRs) with 95% confidence intervals (CIs). The primary endpoint was all-cause mortality. Secondary endpoints included composite cardiovascular events, cardiovascular mortality, heart failure hospitalization, and stroke. Heterogeneity was assessed using the I 2 statistic. Results: Four randomized trials comprising 1,427 patients were included (719 early AVR/TAVR and 708 surveillance). The weighted mean age was 73.3 years, approximately two-thirds were male, and the weighted mean follow-up duration was 49.8 months. Participants were predominantly low surgical risk with preserved left ventricular ejection fraction and severe or very severe AS. Follow-up ranged from 3.8 years in EARLY TAVR to 10 years in RECOVERY. Early AVR/TAVR was associated with a numerically lower risk of all-cause mortality that did not reach statistical significance (HR 0.69, 95% CI 0.42–1.13; P=0.137; I 2 =63.4%). However, early intervention significantly reduced composite cardiovascular events (HR 0.51, 95% CI 0.37–0.72; P<0.001; I 2 =34.9%), cardiovascular mortality (HR 0.40, 95% CI 0.26–0.63; P<0.001; I 2 =0%), heart failure hospitalization (HR 0.39, 95% CI 0.26–0.59; P<0.001; I 2 =0%), and stroke (HR 0.57, 95% CI 0.35–0.93; P=0.026; I 2 =0%). Conclusions: Among randomized trials, early AVR in asymptomatic severe AS significantly reduced major cardiovascular events, cardiovascular mortality, heart failure hospitalization, and stroke compared with conservative surveillance. Although a statistically significant reduction in all-cause mortality was not observed, the overall treatment effect consistently favored earlier intervention. These findings support consideration of an early AVR strategy in carefully selected asymptomatic patients and further reinforce the evolving role of valve intervention before symptom onset.
No takes yet. Share an insight, caveat, or question.
Elzalabany et al. (2026) conducted a meta-analysis in Asymptomatic severe aortic stenosis (n=1,427). Early aortic valve replacement (SAVR or TAVR) vs. Conservative surveillance was evaluated on All-cause mortality (HR 0.69, 95% CI 0.42-1.13, p=0.137). Early AVR did not reduce all-cause mortality vs surveillance, but reduced composite CV events.
Synapse has enriched 10 related papers. Consider them for comparative context: